Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07523022

Comparison of the Effect of Gonadotropin and Clomiphene Citrate Treatment on Sperm Parameters and the Outcome of Assisted Reproductive Procedures in Subfertile Men Based on the APHRODITE Groups

Men enrolled in the study are assigned to each APHRODITE group. Group 2,3,4 are treated with either gonadotropin preparations or clompihene-citrate (except group 4). The type of the treatment (gonadotropin vs clomiphene) is randomized. After treatment, hormonal measurements, spermiogram and DNA fragmentation tests are repeated, allowing for analysis of the outcome.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 4

Primary location

Reproductive Medicine Centre, Department of Obstetrics and Gynecology, University of Szeged

Szeged, 6724, Hungary

About this study

Our research involves male partners of couples suffering from male infertility. After a comprehensive andrological examination, based on the test results, the men are classified into so-called "APHRODITE" categories. Based on these categories, half of the patients are given so-called gonadotropin treatment (the exact treatment depends on the type of category), which involves subcutaneous injections several times a week for a total of 12 weeks. The other half of the patients are recommended oral tablets containing the active ingredient clomiphene citrate, also for 12 weeks. It is important that both types of therapy (gonadotropin and clomiphene citrate) are effective treatments in certain cases of male infertility, according to the literature, so all patients participating in the research receive effective treatment. However, it is decided who receives which treatment by randomization.

After the 12-week treatment, a control sperm analysis and a DNA fragmentation test are performed to determine the success of the treatment (changes in sperm analysis results and DNA fragmentation index).

The improvement in sperm parameters will be determined in the two treatment regimens, the rate of fertilized eggs in subsequent assisted reproduction cycles, the quality of the resulting embryos, and the rate of pregnancies and subsequent losses. The results of the two therapeutic modalities will be compared, so that it can be decided which treatment method is more effective.

The research process is essentially as follows:

  • information, examination
  • classification into the APHRODITE category based on the results
  • randomization (gonadotropin or clomiphene citrate)
  • injection treatment for patients in the gonadotropin group, with therapy according to the APHRODITE category for 12 weeks
  • tablet treatment for patients in the clomiphene citrate group for 12 weeks
  • control spermiogram and DNA fragmentation
  • analysis of the results of subsequent assisted reproduction procedures

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • abnormal sperm analysis result, APHRODITE 2,3,4 categories

Exclusion criteria

  • obstructive azoospermia
  • non-obstructive azoospermia due to genetical defects (Klinefelter-syndrome, AZFa, AZFb microdeletion syndrome etc)
  • problems with the administration of subcutaneous injections
  • disagreement

Treatment and study plan

recFSH

Drug

recFSH 3x150NE sc weekly for 12 weeks

Other names: recombinant FSH

HCG injection

Drug

hCG 2x5000NE sc weekly for 12 weeks

Other names: human chorionic gonadotropin, choriogonadotropin alfa

Clomiphene Citrate 50 mg

Drug

clompihene-citrate 50mg p.o. daily for 12 weeks

Other names: CC

Primary outcomes

  1. sperm DNA fragmentation

    Time frame: 12 weeks of treatment

    sperm DNA fragmentation Index (%), high DNA stainability (%) are measured and compared to the pretreatment values. Lower numbers mean improvement in this outcome.

  2. ejaculate volume

    Time frame: 12 weeks of treatment

    ejaculate volume (ml) after treatment are assessed and compared to the pretreatment values. Higher number means improvement in this outcome.

  3. sperm concentration

    Time frame: 12 weeks

    Sperm concentrations (million/ml) before and after the treatment are compared. Higher number means improvement in this outcome.

  4. sperm motility

    Time frame: 12 weeks

    Sperm total motility (%), progressive motility (%) after the treatment are compared to the pretreatment values. Higher numbers mean improvement in this outcome.

  5. total sperm count, total functional sperm count

    Time frame: 12 weeks

    Total sperm count (million) = ejaculate volume (ml) x sperm concentration (million/ml) and total functional sperm count (million) = total sperm count x progressive motility x 100 are compared before and after the treatment. Higher numbers mean improvement in this outcome.

  6. Sperm morphology

    Time frame: 12 weeks

    Percent of normal sperm morphology (%) is counted after the treatment and compared to the pretreatment result. Higher number mean improvement in this outcome.

Secondary outcomes

  1. gonadotropin vs clomiphene - total sperm count, total functional sperm count

    Time frame: 12 weeks of treatment

    in the APHRODITE 2 and 3 groups, the results of the gonadotropin and clomiphene-citrate arms are compared regarding the percent of patients with improvement in total sperm count (million) and total functional sperm count (million)

  2. gonadotropin vs clomiphene - DNA fragmentation

    Time frame: 12 weeks

    in the APHRODITE 2 and 3 groups, the results of the gonadotropin and clomiphene-citrate arms are compared regarding the percent of patients with improvement in DNA fragmentation Index (%) and high DNA stainability (%)

  3. Gonadotropin vs clomiphene - sperm total motility, progressive motility

    Time frame: 12 weeks

    in the APHRODITE 2 and 3 groups, the results of the gonadotropin and clomiphene-citrate arms are compared regarding the percent of patients with improvement in total sperm motility (%) and progressive sperm motility (%)

  4. gonadotropin vs clomiphene - normal sperm morphology

    Time frame: 12 weeks

    in the APHRODITE 2 and 3 groups, the results of the gonadotropin and clomiphene-citrate arms are compared regarding the percent of patients with improvement in normal sperm morphology (%)

Other outcomes

  1. Gonadotropin hormones

    Time frame: 12 weeks of treatment

    serum FSH (IU/l), LH (IU/l) are measured after the treatment and compared to the pretreatment values.

  2. Testosterone level

    Time frame: 12 weeks

    Total testosterone (nmol/l) is measured after the treatment and compared to the pretreatment values.

  3. Estradiol level

    Time frame: 12 weeks

    Estradiol (pmol/l) are measured after the treatment and compared to the pretreatment results

Sponsors and collaborators

Lead sponsor

Szeged University

Other

Registry information

Acronym: GONACLO

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Apr 13, 2026
Registry last updated
Apr 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.